ABBISKO-B Initiates First Patient Dosing in Phase I Trial for Novel Pan-KRAS Inhibitor

Stock News

Aug 31

ABBISKO-B has announced that its subsidiary, Shanghai Abbisko Biopharmaceutical Co., Ltd., has completed the first patient dosing in a Phase I clinical trial for ABSK211, an oral, high-potency, small-molecule pan-KRAS inhibitor designed to broadly target multiple KRAS alterations.

The trial is evaluating ABSK211 in patients with advanced solid tumors harboring KRAS gene mutations. This milestone marks a significant step forward in the development of this investigational therapy, which aims to address a wide range of KRAS-driven cancers.

By covering various KRAS changes, ABSK211 holds potential as a versatile treatment option for patients whose tumors exhibit these specific genetic alterations, representing a promising approach in oncology.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1185737367"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185737367\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185737367?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185737367","market":"sg","top_or_hot":-1,"title":"ABBISKO-B Initiates First Patient Dosing in Phase I Trial for Novel Pan-KRAS Inhibitor","media":"Stock News","content":"<p><b>ABBISKO-B</b> has announced that its subsidiary, Shanghai Abbisko Biopharmaceutical Co., Ltd., has completed the first patient dosing in a Phase I clinical trial for ABSK211, an oral, high-potency, small-molecule pan-KRAS inhibitor designed to broadly target multiple KRAS alterations.<br><br>The trial is evaluating ABSK211 in patients with advanced solid tumors harboring KRAS gene mutations. This milestone marks a significant step forward in the development of this investigational therapy, which aims to address a wide range of KRAS-driven cancers.<br><br>By covering various KRAS changes, ABSK211 holds potential as a versatile treatment option for patients whose tumors exhibit these specific genetic alterations, representing a promising approach in oncology.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ABBISKO-B Initiates First Patient Dosing in Phase I Trial for Novel Pan-KRAS Inhibitor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nABBISKO-B Initiates First Patient Dosing in Phase I Trial for Novel Pan-KRAS Inhibitor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-31 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>ABBISKO-B</b> has announced that its subsidiary, Shanghai Abbisko Biopharmaceutical Co., Ltd., has completed the first patient dosing in a Phase I clinical trial for ABSK211, an oral, high-potency, small-molecule pan-KRAS inhibitor designed to broadly target multiple KRAS alterations.<br><br>The trial is evaluating ABSK211 in patients with advanced solid tumors harboring KRAS gene mutations. This milestone marks a significant step forward in the development of this investigational therapy, which aims to address a wide range of KRAS-driven cancers.<br><br>By covering various KRAS changes, ABSK211 holds potential as a versatile treatment option for patients whose tumors exhibit these specific genetic alterations, representing a promising approach in oncology.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BPRC5H50.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1185737367","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185737367","pubTimestamp":1788135744,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ABBISKO-B has announced that its subsidiary, Shanghai Abbisko Biopharmaceutical Co., Ltd., has completed the first patient dosing in a Phase I clinical trial for ABSK211, an oral, high-potency,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","PSYK":"PSYK ETF","BK1161":"生物科技","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","02256":"和誉-B","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","MDTX":"Corgi MediaTek 2x Daily ETF","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"ABBISKO-B 在新型 Pan-KRAS 抑制剂的 I 期试验中启动首次患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":1,"PSYK":1,"02256":1,"MDTX":1,"BMED":1,"IBBJ":1},"content_text":"ABBISKO-B has announced that its subsidiary, Shanghai Abbisko Biopharmaceutical Co., Ltd., has completed the first patient dosing in a Phase I clinical trial for ABSK211, an oral, high-potency, small-molecule pan-KRAS inhibitor designed to broadly target multiple KRAS alterations.The trial is evaluating ABSK211 in patients with advanced solid tumors harboring KRAS gene mutations. This milestone marks a significant step forward in the development of this investigational therapy, which aims to address a wide range of KRAS-driven cancers.By covering various KRAS changes, ABSK211 holds potential as a versatile treatment option for patients whose tumors exhibit these specific genetic alterations, representing a promising approach in oncology.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}